Date

Vol.

No.

SWITCH Special Reports

April/May 2001

7

6

FDA Meeting (May 11,2001)

Testimony by Steve Francesco to the FDA Regarding the Potential Switch of Non-Sedating Antihistamines

Oct./Nov. 2001

8

2

Hypertension

Chronic Therapy Switch Market Segmentation Template

Dec. 2001/Jan. 2002

8

3

Hypertension

Potential Hypertension Self-Management Outcomes

June/July 2001

8

1

OTC Treatment and Inhibitors

Dec. 2000/Jan. 2001

7

4

Year 2000-All the Major Rx-to-OTC Switches
-United States
-United Kingdom
-Germany
-France
-Japan
-Sweden

Feb./Mar. 2001

7

5

Year 2000 Multinational Regulatory Status

1. Loratidine
2. Fexofenidine
3. Cetirizine

Date

Vol.

No.

SWITCH Forecast

June/July 2001

8

1

Focus on Europe

• Gap Widens Between UK & Continental Europe on Rx-to-OTC Switches
• Public Health Platitudes & Attitudes Hinder Progress

Oct./Nov. 2001

8

2

Hypertension Treatment in an OTC Context: (Part ONE)

The Potential Rx-to-OTC Switch of the Hypertension Indication Opportunities and 10 Year Evolution

Dec. 2001/Jan. 2002

8

3

Hypertension Treatment in an OTC Context: (Part TWO)

The Hypertension Switch Model: 4 Major Building Blocks

Feb./Mar. 2001

7

5

The Inevitable Switch and Dual Status of Non-Sedating Antihistamines in the US

Insurer Blue Cross Gains Advisory Committee Meeting for Non-Sedating Antihistamine Switch

April/May 2001

7

6

US FDA Advisory Committee Supports Wellpoint Recommendation to Switch Non-Sedating Antihistamines

• Will Rivet-Popping Cost Pressures Burst Open the Current Status Quo?
• Do the Drug Makers Have a Contingency Plan?

Dec. ‘00/Jan. 2001

7

4

Year 2000 in Switches: A Disastrous Year

• But, the OTC Evolutionary Stage of “Broarder Access” is Here
• Evidenced by the Global Emergency to Switch the Emergency Contraceptive Pill

Date

Vol.

No.

SWITCH Scene/Country Update/Noteables/Other

April/May 2001

7

6

Dual Status

Scene:  The Battle for Healthcare Resources & Switch:

• Dual Status Should Be a Goal for Each Country’s Drug Development.  That Way Budgets Go Further.

Oct../Nov. 2001

8

2

Hypertension

Chronic Therapy Switch (Hypertension) Market Segmentation Template

Dec. 2000/Jan. 2001

7

4

OTC Growth

Scene:  The Japanese MHW’s Request for “Actual Use” and Post Marketing Studies.  Hope for OTC Growth?

• The German Preference for OTC Reimursement

Country Summary: Year 2000 Switch – All the Major Rx-to-OTC Switch Events of the Year, Including Switch Issues & Molecules 

Feb./Mar. 2001

7

5

Rx-to-OTC Switch Activity

Scene:  Reflections on the Last Twenty Months of US Rx-to-OTC Switch Activity

Country Summary: UK, Netherlands & Denmark

June/July 2001

8

1

SWITCH® Anniversary Publisher’s Letter:

New Products and Services for You

Country Update: Germany, UK, Canada, Japan, US

Dec. 2001/Jan. 2002

8

3

Year 2000 Switch Rate

Scene:  THE Story for 2001: Governments Take On the Dismal Switch Rate

• UK’s MCA and US’s FDA Fuel the Fire for More Switches in 2002
• How Far Will the Pendulum Swing Away from Pharma’s Control?

Date

Vol.

No.

SWITCH Charts

April/May 2001

7

6

FDA & Managed Care

• FDA Testimony Charts on the Switch of Non-Sedating Antihistamines
• 1998 Top 10 Drugs in Managed Care Ranked by PMPY Dollars and Rxs/1000 Members

Oct../Nov. 2001

8

2

Hypertension Charts

• 10 Year Rx Sales
• Competitive Matrix by Class Year 2000
• Competitive Matrix by Class Year 2010

Dec. 2001/Jan. 2002

8

3

Hypertension Charts

• MD/Self-Medication Hypertension Diagnosis Continuum
• Rx-to-OTC Switch Major Markets (1995-2001)
• All the Major Switches of 2001

Feb./Mar. 2001

7

5

Non-Sedating Antihistamines

• US Sales & Shares 1997-2001
• Major Global Competitors
• Regulatory Status Around the World

June/July 2001

8

1

OTC Switches & Growth

• The Diagnosis/Duration of Treatment Matrix for Rx-to-OTC Switches
• The 13 Inhibitors to OTC Growth in Europe

Dec. 2000/Jan. 2001

7

4

Rx-to-OTC Switches

• The Four Stages of OTC Evolution
•   Year Record of Sales
• New Molecule Switches of the Year 2000
• SWITCH® 2000 Index
• Japanese OTC Market Latest Fiscal Year